Lucence
Develops ultra-sensitive liquid biopsy tests for multi-cancer early detection and profiling.
What they do
Lucence designs and manufactures ultra-sensitive blood tests utilizing proprietary amplicon-based sequencing technology. Clinical oncologists use its LiquidHALLMARK assay to detect cancer mutations with high specificity, helping guide personalized treatment selection and therapeutic monitoring.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer screening and diagnostics
- Product type
- Diagnostics
- Stage
- Series B
- Headquarters
- Singapore
- Region
- Asia-Pacific
- Founded
- 2016
- Total funding
- $29M raised
Notable investors: Luminate Medical, Heliconia Capital Management, Lim Ho Kee.